Jason P Simon

US Patent:

8535887, Sep 17, 2013

Filed:

May 21, 2010

Appl. No.:

12/785060

Inventors:

Arthur Bertelsen - Ridgewood NJ, US
Jacques Fellay - Durham NC, US
Dongliang Ge - Raleigh NC, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Durham NJ, US
Thomas Urban - Durham NC, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435 611, 435 5, 435 61, 435 612

Abstract:

The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients.

US Patent:

20070136688, Jun 14, 2007

Filed:

Dec 8, 2005

Appl. No.:

11/299157

Inventors:

Eugene Mirkin - Cupertino CA, US
Jason Simon - Campbell CA, US

International Classification:

G06F 17/00

US Classification:

715816000

Abstract:

A method of inputting text in an electronic device () including a display () and an input user interface () having a plurality of keys () arranged in a predetermined pattern includes a plurality of steps. In a first step, a list of potential characters is compiled and includes at least one subset less than or equal in number to the number of keys in the keypad matrix () on the input user interface (). The first subset from the list of potential characters is displayed in an arrangement corresponding to the position of the keys (). The desired character selection is received by sensing actuation of a key on the input user interface () corresponding to the position of a character on the display ().

US Patent:

20130251677, Sep 26, 2013

Filed:

May 30, 2013

Appl. No.:

13/905987

Inventors:

Jacques Fellay - St. Maurice, CH
Dongliang Ge - Foster City CA, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Fitzroy North Victoria, AU
Thomas Urban - Durham NC, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12Q 1/68
G06F 17/18
A61K 38/21

US Classification:

424 857, 435 611, 435 5, 702 19

Abstract:

The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients.

US Patent:

20180209980, Jul 26, 2018

Filed:

Mar 23, 2018

Appl. No.:

15/934242

Inventors:

- Tokyo, JP
Tadashi Kadowaki - Tsukuba, JP
Junji Matsui - Tsukuba, JP
Jason S. Simon - Woodcliff Lake NJ, US
Lucy Xu - Woodcliff Lake NJ, US

Assignee:

Eisai R&D Management Co., Ltd. - Tokyo

International Classification:

G01N 33/574
C12Q 1/6886
A61K 31/47

Abstract:

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

US Patent:

20140187577, Jul 3, 2014

Filed:

May 31, 2012

Appl. No.:

14/122339

Inventors:

Yasuhiro Funahashi - Tsukuba-shi, JP
Tadashi Kadowaki - Tsukuba-shi, JP
Junji Matsui - Tsukuba-shi, JP
Jason S. Simon - Woodcliff Lake NJ, US
Lucy Xu - Woodcliff Lake NJ, US

Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo

International Classification:

G01N 33/574
A61K 31/47
C12Q 1/68

US Classification:

514312, 435 611, 435 792

Abstract:

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.